Dr Agarwal's Hea

Why is Dr Agarwals Health Care Ltd falling/rising?

As of 03-Aug, Dr Agarwals Health Care Ltd's stock price is rising to 483.75, reflecting a 0.97% increase. This rise is driven by a trend reversal after previous declines, strong financial health, and high institutional backing, despite a drop in investor participation.

As of 03-Aug, Dr Agarwals Health Care Ltd's stock price is rising, currently at 483.75, reflecting an increase of 4.65 (0.97%). This upward movement can be attributed to several factors. Firstly, the stock has shown a trend reversal, gaining after three consecutive days of decline. Additionally, it outperformed its sector by 1.83% today, indicating stronger performance relative to peers.<BR><BR>The stock reached an intraday high of Rs 494.9, which is a 3.3% increase, showcasing positive momentum. Despite a decrease in investor participation, with delivery volume falling by 47.36% against the 5-day average, the stock remains liquid enough for trading, suggesting that there is still interest among investors.<BR><BR>Moreover, the company has demonstrated strong financial health, with a low Debt to EBITDA ratio of 1.87 times, indicating a strong ability to service its debt. The company has also reported healthy long-term growth, with net sales increasing at an annual rate of 26.90%. Positive results over the last five consecutive quarters further bolster investor confidence, as evidenced by the highest net sales and operating profit to interest ratios reported.<BR><BR>Lastly, high institutional holdings at 65.68% suggest that knowledgeable investors are backing the stock, which can provide additional stability and support for its price. Overall, these factors contribute to the current rise in the stock price of Dr Agarwals Health Care Ltd.

Which are the latest news on Dr Agarwal's Hea?

When is the next results date for Dr Agarwals Health Care Ltd?

The next results date for Dr Agarwals Health Care Ltd is August 4, 2026.

The next results date for Dr Agarwals Health Care Ltd is scheduled for August 4, 2026.

What does Dr Agarwal's Hea do?

Dr Agarwal's Health Care Ltd is a small-cap company in the hospital industry, reporting net sales of 564 Cr and a net profit of 40 Cr for March 2026, with a market cap of INR 14,220 Cr. Key metrics include a P/E ratio of 107.00 and a debt-equity ratio of 0.39.

Overview: <BR>Dr Agarwal's Health Care Ltd operates in the hospital industry and is categorized as a small-cap company.<BR><BR>History: <BR>The company was incorporated in 2010 and commenced operations shortly thereafter. The latest quarterly results reported are for March 2026, showing net sales and profit figures.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 564 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 40 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 14,220 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 107.00 <BR>Industry P/E: 60 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.39 <BR>Return on Equity: 6.53% <BR>Price to Book: 7.01<BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

How big is Dr Agarwal's Hea?

As of 10th June, Dr Agarwals Health Care Ltd has a market capitalization of 14,220.00 Cr, with recent net sales of 2,080.08 Cr and a net profit of 133.19 Cr.

As of 10th June, Dr Agarwals Health Care Ltd has a market capitalization of 14,220.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 2,080.08 Cr and a Net Profit of 133.19 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 1,866.59 Cr and Total Assets of 3,639.60 Cr.

Who are the peers of the Dr Agarwal's Hea?

Dr Agarwal's Hea's peers include Fortis Health, Aster DM Health, Narayana Hrudaya, Global Health, Krishna Institute, Rainbow Child, Jupiter Life Line, and Yatharth Hospital. In terms of management risk, Dr Agarwal's Hea has an average rating, with a 1-year return of 22.69%, higher than Rainbow Child but lower than Aster DM Health's 41.97%.

Peers: The peers of Dr Agarwal's Hea are Fortis Health., Aster DM Health., Narayana Hrudaya, Global Health, Krishna Institu., Rainbow Child., Health.Global, Jupiter Life Lin, and Yatharth Hospit.<BR><BR>Quality Snapshot: Excellent management risk is observed at Narayana Hrudaya, Global Health, and Jupiter Life Lin, while Good management risk is found at Aster DM Health., Krishna Institu., Rainbow Child., and Yatharth Hospit. Average management risk is noted for Fortis Health. and Health.Global, and Dr Agarwal's Hea has Average management risk. In terms of growth, Excellent growth is seen at Fortis Health. and Narayana Hrudaya, while Good growth is reported for Dr Agarwal's Hea and Yatharth Hospit. Below Average growth is present at Aster DM Health., Global Health, Krishna Institu., and Rainbow Child. The Capital Structure is Excellent for Global Health and Jupiter Life Lin, Good for Fortis Health., Dr Agarwal's Hea, Krishna Institu., Rainbow Child., and Yatharth Hospit., and Average for Aster DM Health. and Health.Global.<BR><BR>Return Snapshot: Aster DM Health. has the highest 1-year return at 41.97%, while Rainbow Child. has the lowest at -3.06%. Dr Agarwal's Hea's 1-year return is 22.69%, which is higher than Rainbow Child. but lower than Aster DM Health. Additionally, Health.Global and Jupiter Life Lin have negative six-month returns.

Are Dr Agarwals Health Care Ltd latest results good or bad?

Dr Agarwal's Health Care Ltd reported strong Q4 FY26 results, with a net profit of ₹39.71 crore (up 21.92%) and net sales of ₹564.11 crore (up 22.57%). The operating margin reached a record high of 28.62%, indicating effective cost management and positive future prospects.

Dr Agarwal's Health Care Ltd has reported strong results for Q4 FY26, indicating a positive performance overall. The company achieved a consolidated net profit of ₹39.71 crore, which reflects a year-on-year increase of 21.92%. Revenue also saw substantial growth, with net sales reaching ₹564.11 crore, representing a 22.57% increase compared to the same quarter last year.<BR><BR>Additionally, the operating margin (excluding other income) reached a record high of 28.62%, demonstrating effective cost management and operational efficiency. This is an improvement from the previous quarters, indicating the company's ability to scale operations while maintaining pricing discipline.<BR><BR>Overall, the results are quite favorable, showcasing robust revenue growth and improved profitability metrics, which are positive indicators for the company's future performance in the competitive healthcare sector.

Should I buy, sell or hold Dr Agarwals Health Care Ltd?

How has been the historical performance of Dr Agarwal's Hea?

Dr Agarwal's Hea has shown significant growth over the past three years, with net sales increasing from 1,017.98 Cr in Mar'23 to 1,711.00 Cr in Mar'25, and operating profit rising from 283.86 Cr to 502.40 Cr during the same period, alongside a substantial increase in total assets. Overall, the company demonstrates a solid performance trajectory with rising revenues and profits.

Answer:<BR>The historical performance of Dr Agarwal's Hea shows significant growth in various financial metrics over the past three years.<BR><BR>Breakdown:<BR>Dr Agarwal's Hea has demonstrated a strong upward trend in net sales, increasing from 1,017.98 Cr in Mar'23 to 1,711.00 Cr in Mar'25. Total operating income followed suit, rising from 1,017.98 Cr to 1,711.00 Cr during the same period. The company's total expenditure also grew, reaching 1,254.62 Cr in Mar'25, up from 747.63 Cr in Mar'23. Operating profit (PBDIT) saw a notable increase, climbing from 283.86 Cr in Mar'23 to 502.40 Cr in Mar'25. Profit before tax also improved, moving from 83.59 Cr in Mar'23 to 159.85 Cr in Mar'25, while profit after tax showed a slight fluctuation, peaking at 110.34 Cr in Mar'25 compared to 103.23 Cr in Mar'23. The consolidated net profit remained relatively stable, with a slight increase from 83.06 Cr in Mar'24 to 83.46 Cr in Mar'25. The company's total assets rose significantly from 1,769.72 Cr in Mar'23 to 3,639.60 Cr in Mar'25, reflecting robust growth in shareholder's funds and reserves. Cash flow from operating activities also improved, reaching 360.00 Cr in Mar'25, while cash flow from investing activities remained negative at -750.00 Cr, indicating ongoing investments. Overall, Dr Agarwal's Hea has shown a solid performance trajectory with increasing revenues and profits, alongside a growing asset base.

Is Dr Agarwal's Hea overvalued or undervalued?

As of September 12, 2025, Dr Agarwal's Healthcare is considered very expensive and overvalued with a PE ratio of 160.64, significantly higher than its peers, and a low ROE of 4.58%, making it not a compelling investment at its current price of 433.10.

As of 12 September 2025, the valuation grade for Dr Agarwal's Healthcare has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently deemed overvalued, with a PE ratio of 160.64, a Price to Book Value of 7.36, and an EV to EBITDA of 31.07. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Dr Agarwal's Healthcare stands out with a notably higher PE ratio than Max Healthcare, which has a PE of 95.48, and Apollo Hospitals, which is at 71.91. Additionally, the company's ROE is only 4.58%, which is considerably lower than the industry average, further reinforcing the overvaluation narrative. Despite a recent stock return of 1.55% over the past week, which slightly outperformed the Sensex's 1.48%, the overall valuation metrics suggest that Dr Agarwal's Healthcare is not a compelling investment at its current price of 433.10.

Who are the top shareholders of the Dr Agarwal's Hea?

The top shareholders of Dr Agarwal's Hea are primarily Foreign Institutional Investors (FIIs) with 60.62%, led by Hyperion Investments Pte Ltd at 23.17%. Dr. Athiya Agarwal is the largest individual shareholder at 5.99%, while mutual funds hold 3.84% and individual investors own 1.61%.

The top shareholders of Dr Agarwal's Hea include a mix of institutional and individual investors. The majority of the shares are held by Foreign Institutional Investors (FIIs), who own approximately 60.62% of the company. The highest public shareholder is Hyperion Investments Pte Ltd, holding 23.17%. Among individual stakeholders, Dr. Athiya Agarwal is the promoter with the highest holding at 5.99%. Additionally, mutual funds are represented by six schemes, collectively holding 3.84%. Individual investors account for 1.61% of the shares.

Has Dr Agarwal's Hea declared dividend?

No Dividend History Available